CASE REPORT

Acute necrotic disorder of the small intestine post-coronavirus disease-2019 vaccination

Tomoyuki Nishimura1 | Seiji Onogawa1 | Takuya Yamamoto1 | Yasuhiro Okuda1 | Morito Ikeda1 | Nozomu Matsumoto1 | Keisuke Kurihara1 | Akinori Shimizu1 | Shosuke Kitamura1 | Yoshio Katamura1 | Naomichi Hirano1 | Shingo Itamoto2 | Masahiro Nakahara2 | Shuji Yonehara3 | Fumio Shimamoto4 | Keiji Hanada1

1Department of Gastroenterology, Onomichi General Hospital, Hiroshima, Japan
2Department of Surgery, Onomichi General Hospital, Hiroshima, Japan
3Department of Pathology, Onomichi General Hospital, Hiroshima, Japan
4Department of Nursing, Faculty of Health Sciences, Hiroshima Cosmopolitan University, Hiroshima, Japan

Correspondence
Tomoyuki Nishimura, Department of Gastroenterology, Onomichi General Hospital, 1-10-23, Hirahara, Onomichi, Hiroshima 722-8508, Japan. Email: tomoyuki@hiroshima-u.ac.jp

Abstract
The Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccine is extensively used worldwide, and its safety has been proven. Herein, we report a case of an acute necrotic disorder in the small intestine post-COVID-19 vaccination. The patient developed severe abdominal pain the day after the first vaccination. Contrast-enhanced computed tomography showed extensive ileum wall thickening and ascites. Colonoscopy revealed a ring-shaped ulcer and stricture in the terminal ileum. Ileocecal resection was performed, and the patient did not have further episodes of a necrotic disorder in the small intestine. Although it is unknown if this event is associated with vaccination, and this occurrence also does not outweigh the efficacy and safety of the Pfizer-BioNTech COVID-19 vaccine, gastroenterologists need to be aware of this rare case, given its noteworthy timing.

KEYWORDS
COVID-19, necrosis, side effects, small intestine, vaccines

INTRODUCTION

The coronavirus disease-2019 (COVID-19) emerged in China in 2019 and rapidly spread worldwide. It was caused by the severe acute respiratory syndrome coronavirus 2 and resulted in multiple severe cases and deaths.1 On December 11, 2020, the US Food and Drug Administration granted emergency approval to Pfizer-BioNTech’s COVID-19 vaccine, which was extensively administered worldwide. Pfizer’s COVID-19 vaccine uses a pioneering messenger RNA (mRNA) technology that has never been used previously in vaccine production, and several concerns arose regarding its side effects. However, the previously reported side effects rarely required hospitalization.2 In this report, we discuss a case of an acute necrotic disorder of the small intestine that required surgical resection in a patient after he received the first dose of the Pfizer-BioNTech COVID-19 vaccine.

CASE REPORT

A 72-year-old male visited the emergency department complaining of acute-onset abdominal pain. He had received his first dose of the Pfizer-BioNTech BNT162B2b mRNA vaccine one day before visiting the hospital. He had a history of cerebral infarction and
immunoglobulin G (IgG) 4-related kidney disease. His current medications were clopidogrel (75 mg) and prednisolone (5 mg). He was conscious and afebrile. Physical examination revealed abdominal tenderness without rebound tenderness or guarding. He had decreased bowel sounds and normal vital signs. Laboratory testing revealed a slightly elevated white blood cell count of 14,400/µl (reference range, 3300–8600/µl). Other markers, including D-dimer, were normal. He was admitted to the hospital for suspected enteritis.

One day after his admission, the abdominal pain worsened. His white blood cell count was elevated to 17,100/µl, C-reactive protein level was 13.70 mg/dl (reference value, < 0.14 mg/dl), and D-dimer level was 4.6 µg/ml (reference range, 0–1 µg/ml). Contrast-enhanced computed tomography showed extensive ileum wall thickening and ascites; there were no abnormal findings in the vessels around the terminal ileum (Figure 1). These findings were likely manifestations of enteritis exacerbation. Thus, the patient was instructed to fast and was initially treated with broad-spectrum intravenous antibiotics. However, as the symptoms failed to improve, IgG4-related enteritis was suspected. Prednisolone (40 mg) was administered on day 4 of hospitalization, but it was ineffective. The abdominal pain became more severe, and he developed diarrhea and fever. Surgical resection of the bowel was considered; however, the patient refused it. Blood and stool cultures showed unremarkable results. Colonoscopy performed on day 32 revealed a ring-shaped ulcer and stricture in the terminal ileum with normal findings in the large intestine (Figure 2). These findings were consistent with acute necrotic small bowel inflammation and few IgG4-positive cells were noted. Postoperatively, his fever and abdominal pain improved, and he was discharged on a postoperative day 14 without major complications. No new events have occurred since discharge.

**DISCUSSION**

Among patients with COVID-19, both arterial and venous thrombosis are reportedly noted in those with a strong thrombotic tendency. Specifically, cerebral infarction, myocardial infarction, and limb artery thrombosis have been reported as arterial thrombosis events, while deep vein thrombosis and pulmonary thromboembolism have been reported as venous thrombosis events. Additionally, prophylactic anticoagulant therapy has not been associated with a reduction in thrombosis incidence. In this case, severe necrotic small bowel inflammation occurred despite the use of anticoagulant medication.
Ulceration and necrosis were observed in the ileocecal region.

The laminar structure of the intestinal tract was replaced almost entirely by inflammatory granulation tissue. Berlin blue staining showed hemosiderin-phagocyted macrophages.

Three vaccines have been approved in Japan: two mRNA vaccines, developed by Pfizer/BioNTech and Moderna, and the virus vector vaccine, developed by AstraZeneca. These vaccines do not contain a live virus.

Although genetic information is inoculated into the body, it does not alter human genetic information. In addition, the mRNA is broken down within a few days after vaccination, and the spike protein produced disappears.
within two weeks after vaccination. Based on the mechanism of the mRNA vaccine, few adverse reactions are expected.

Mild, local, and systemic reactions have been reported in patients recently vaccinated against COVID-19. According to Chapin-Bardales et al., the most frequently reported local and systemic reactions after the first COVID-19 vaccine dose were injection site pain (67.8%), fatigue (30.9%), headache (25.9%), and myalgia (19.4%). Reactogenicity was substantially greater after the second dose for both vaccines, particularly for systemic reactions, including fatigue (53.9%), headache (46.7%), myalgia (44.0%), chills (31.3%), fever (29.5%), and joint pain (25.6%). Abdominal pain was observed in 3.0% of patients after their first dose and in 6.1% after their second dose. However, severe thrombosis was not observed. In previous reports, most adverse events after COVID-19 vaccination were mild or moderate. However, severe thrombosis with thrombocytopenia has also been identified as an adverse reaction. Since March 2021, several case series of unusual thrombotic events and thrombocytopenia have been reported in Germany, Norway, and the UK. However, there have been no reports of small intestinal disorders after COVID-19 vaccination. On April 7, 2021, the European Medicines Agency concluded that the condition should be listed as an “infrequent adverse reaction, considered similar to heparin-induced thrombocytopenia. Tarawneh et al. reported that a 22-year-old healthy man developed severe thrombocytopenia three days after receiving the Pfizer-BioNTech BNT16B2b mRNA vaccine. In our case, thrombocytopenia did not occur. However, findings, such as an elevated D-dimer level, suggested necrotic disorder. This was a rare case of severe necrotic disorder that developed immediately after vaccination. However, it is unknown if this event is associated with vaccination. There is a possibility of an accidental complication. This occurrence also does not outweigh the efficacy and safety of the Pfizer-BioNTech BNT16B2b mRNA vaccine. We believe that reporting this case is important to create awareness among clinicians to watch for and report similar cases for the accumulation of data.

CONFLICT OF INTEREST
The authors declare that they have no conflict of interest.

FUNDING INFORMATION
None.

ETHICS STATEMENT
Not applicable.

ORCID
Tomoyuki Nishimura
https://orcid.org/0000-0002-0018-5960

REFERENCES
1. Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. Lancet 2020; 395:1014–5.
2. El-Shitany NA, Harakeh S, Badr-Eldin SM et al. Minor to moderate side effects of Pfizer-BioNTech COVID-19 vaccine among Saudi residents: A retrospective cross-sectional study. Int J Gen Med 2021; 14:1389–401.
3. Fraissé M, Logre E, Pajot O, Mentec H, Plantefève G, Contou D. Thrombotic and hemorrhagic events in critically ill COVID-19 patients: A French monocenter retrospective study. Crit Care 2021; 24:275.
4. Klok FA, Kruip MJHA, van der Meer NJM et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res 2020; 19:148–50.
5. Chapin-Bardales J, Gee J, Myers T. Reactogenicity following receipt of mRNA-based COVID-19 vaccines. JAMA 2021; 325:2201–2.
6. Walsh EE, Frenck RW, Falsey AR et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med 2020; 382:2439–50.
7. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021; 384:2092–101.
8. Schultz NH, Servoli IH, Michelsen AE et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021; 384:2124–30.
9. Scully M, Singh D, Lown R et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021; 384:2202–11.
10. Tarawneh O, Tarawneh H. Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine. Am J Hematol 2021; 96:E133–4.